Ustekinumab biosimilar switch tied to stable Crohn’s outcomes at six months

Share

Switching clinically stable patients with Crohn’s disease from reference ustekinumab to a biosimilar maintained disease control over six months, an Italian study found. Outcomes were similar to those among patients who continued reference treatment.

At six months, 92% of patients who switched and 93% who continued reference ustekinumab remained in clinical remission without corticosteroid use, treatment discontinuation, hospitalization for inflammatory bowel disease (IBD), or intestinal surgery.

The investigators had set 15 percentage points as the largest drop in clinical success they would accept, a margin they described as relatively permissive. The observed gap was half a percentage point, and the range of values consistent with the data stayed well inside a stricter 10-point benchmark the authors added after the analysis.

However, the findings do not establish that the treatments are equivalent or interchangeable over the long term, cautioned first author Davide Giuseppe Ribaldone, MD, PhD, a consultant gastroenterologist at the University of Turin, Italy.

Davide Giuseppe Ribaldone, MD, PhD

“Crohn’s disease-specific real-world evidence on ustekinumab biosimilar switching has been limited, particularly from prospective studies with a concurrent reference-treatment group,” Dr. Ribaldone told GI & Hepatology News. “These findings support the effectiveness of switching in comparable, clinically stable patients and provide reassurance about its short-term safety.”

The investigator-initiated USBIOS study, published in Clinical Gastroenterology and Hepatology, included 462 adults with Crohn’s disease at 18 Italian IBD centers. All had received reference ustekinumab for at least eight months, had a Harvey-Bradshaw Index score below 5, and had been free of corticosteroids for at least that long.

Regional purchasing decisions determined which treatment patients received. Overall, 337 switched to one of three ustekinumab biosimilars — SB17 (Pyzchiva), CT-P43 (Steqeyma), or AVT04 (Uzpruvo) — while 125 continued reference ustekinumab. Patients had received reference ustekinumab for a median of nearly 30 months, and 82% had previously received a tumor necrosis factor inhibitor. Measured baseline characteristics were generally similar, although among patients who had undergone endoscopy, ulcerations at the start of the study were more common in those who switched than in those who continued reference treatment, 29% vs. 16%.

Clinical success meant remaining in remission without systemic corticosteroids, stopping ustekinumab or another anti-interleukin-12/23 treatment, hospitalization for IBD, or intestinal surgery.

Complete data were available for 332 patients who switched and 123 who continued reference ustekinumab. Clinical success was achieved by 306 and 114 patients, respectively.

Results were similar using the study’s original definition of clinical success, which did not include hospitalization or surgery. About 93% of patients in both groups met that measure. After researchers used propensity-score weighting to account for measured differences between the groups, success rates remained similar at 93% after switching and 94% with continued reference treatment. Residual confounding could not be excluded, the authors noted.

Steroid-free clinical remission occurred in 95% of both groups. Six patients who switched and two who continued reference ustekinumab received systemic corticosteroids. Four and two patients, respectively, were hospitalized for IBD. Three patients who switched underwent intestinal surgery, compared with none who continued reference treatment.

Based on C-reactive protein and fecal calprotectin levels, biochemical remission occurred in 50% of patients who switched and 52% who continued reference treatment, among those with available laboratory data. The lower biochemical remission rates suggest that symptoms alone may not reflect ongoing inflammation, supporting continued biomarker monitoring, the authors noted.

Available intestinal ultrasound and endoscopy results showed no greater disease worsening after switching. However, the analyses included only some patients, and the results were not reviewed centrally.

Among 334 patients with available data, 94% remained on their assigned biosimilar at six months. Four patients, or 1%, returned to reference ustekinumab. Two adverse events were reported after switching, both with CT-P43: oral burning with altered taste and itchy skin lesions of unclear cause. No adverse events were reported among patients who continued reference treatment. Adverse events were recorded by treating clinicians rather than through a dedicated pharmacovigilance system, the authors noted.

In exploratory analyses, clinical success rates were 96% with SB17, 92% with CT-P43, and 89% with AVT04. However, the authors cautioned that the biosimilars could not be directly compared because regional policies determined treatment and the groups differed at the start of the study.

Limitations included the nonrandomized design, possible unmeasured differences among regions and centers, and follow-up of only six months. Objective monitoring was not standardized, and researchers did not routinely measure ustekinumab levels or antidrug antibodies. Only four patients received ustekinumab every four weeks, so the findings may not apply to patients receiving intensified treatment.

The study received no grant funding. Several authors reported financial relationships with pharmaceutical companies.

Expert Insight

Dr. Ribaldone discussed the findings with GI & Hepatology News.

How should physicians monitor patients with Crohn’s disease after switching from reference ustekinumab to a biosimilar?

Dr. Ribaldone: Before switching, I would document symptoms, C-reactive protein and fecal calprotectin, providing a baseline against which subsequent changes can be assessed. The established dose and dosing interval should be maintained, and patients should receive clear information about the switch and any differences in the injection device.

A clinical and biomarker assessment approximately three months after switching is a reasonable practical approach, followed by monitoring tailored to the patient’s disease course. This is a clinical suggestion, rather than a monitoring schedule tested by USBIOS.

Symptoms alone are insufficient: our patients were clinically stable, but not all were free of objective inflammation. New symptoms or rising biomarkers should prompt appropriate investigation, including intestinal ultrasound or endoscopy when indicated. Switching alone does not require an additional colonoscopy. Patients should have a clear route to contact their IBD team if concerns arise.

Which patients may not be good candidates for switching based on the limited evidence available?

Dr. Ribaldone: The regulatory context is important here. Both EMA and FDA require robust evidence of biosimilarity, establishing that there are no clinically meaningful differences from the reference product in safety and effectiveness. Both accept scientifically justified extrapolation of indications: a biosimilar can therefore be approved for Crohn’s disease without a separate efficacy trial in Crohn’s disease, provided the overall evidence supports that indication. Physicians can have confidence in these products for their approved uses.

The strongest direct evidence from USBIOS specifically concerns switching in adults in clinical remission who had received reference ustekinumab for at least eight months and had been free of corticosteroids for at least eight months.

In patients with a current flare, recent loss of response, ongoing corticosteroid requirements or recent treatment intensification, the priority is to reassess disease activity and establish an effective treatment strategy. These circumstances fall outside the population adequately represented in our study; they are reasons to individualize management, rather than demonstrated contraindications to ustekinumab biosimilars. Similarly, an elevated biomarker alone is not an established reason to avoid switching, although it warrants assessment.

What longer-term data are needed before physicians can feel confident about biosimilar switching, particularly in patients receiving ustekinumab every four weeks?

Dr. Ribaldone: Only four patients in USBIOS received ustekinumab every four weeks: two in the switch group and two in the reference group. We therefore cannot draw meaningful conclusions about this subgroup.

Larger prospective comparative studies, ideally with at least 12 to 24 months of follow-up and adequate representation of patients receiving every-four-week treatment, would be particularly valuable. They should distinguish patients already stable on intensified maintenance from those undergoing intensification because of loss of response.

Beyond sustained steroid-free clinical remission, these studies should assess biomarkers, endoscopic outcomes, treatment persistence, hospitalization, surgery and delayed adverse events. Serial drug concentrations and antidrug antibodies would help address pharmacokinetic and immunogenicity questions that USBIOS could not evaluate. Repeated switching also deserves dedicated study.